What does ILiAD Biotechnologies do?

ILiAD Biotechnologies is a research organisation in Gent. Private Limited, started on 15 January 2020, 1 establishment.

What is the address of ILiAD Biotechnologies?

The registered office of ILiAD Biotechnologies is located at Technologiepark-Zwijnaarde 94, 9052 Gent.

Is ILiAD Biotechnologies still active?

Yes. According to the CBE (29 October 2026) ILiAD Biotechnologies is active, legal situation “Normale toestand”, started on 15 January 2020.

Is ILiAD Biotechnologies registered on Peppol?

Yes, ILiAD Biotechnologies is registered on the Peppol network with ID 0208:0741579648.

What is the enterprise number of ILiAD Biotechnologies?

The enterprise number of ILiAD Biotechnologies is BE0741579648.

When was ILiAD Biotechnologies founded?

ILiAD Biotechnologies was founded on 15 January 2020.

Who are the directors of ILiAD Biotechnologies?

According to the 2025 annual accounts, the directors of ILiAD Biotechnologies are: Thalen Biotech Consultancy BV, Rubin Keith, David Hinkel.

Is ILiAD Biotechnologies a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 15 January 2020; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did ILiAD Biotechnologies make in 2025?

ILiAD Biotechnologies recorded a loss after taxes of € 76,960 in financial year 2025.

What is the revenue of ILiAD Biotechnologies?

As a small company, ILiAD Biotechnologies is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 1,426,230.

How much does an employee at ILiAD Biotechnologies earn?

The average wage cost per full-time employee at ILiAD Biotechnologies was € 90,000 in 2025: staff costs of € 1.3 million for 14.4 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does ILiAD Biotechnologies have?

According to the 2025 annual accounts, ILiAD Biotechnologies has 14.4 full-time equivalents (FTE).

ILiAD Biotechnologies (Private Limited) - Gent

Dossier ILiAD Biotechnologies, printed on 29 October 2026 from databakkes.be/en/0741579648/iliad-biotechnologies. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 55 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

ILiAD Biotechnologies from Gent, company number BE0741579648, closed financial year 2025 with a result of € -76,960 after tax. For that financial year ILiAD Biotechnologies recorded a gross margin of € 1.4 million and equity of € 25,626. Compared with financial year 2024, the result moved from € -189,421 to € -76,960. The company made a loss. The buffer shrank hard: equity is 75 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2026.

What it is worth Shrank hard

€ 25,626

▼ 75% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -76,960

▲ 59 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 56,305

▼ 62% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -567,119.

People and assets in 2025

Full-time equivalents

14.4

▲ 2 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 1.3 million

▲ 27% vs 2024

€ 90,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 26,666

▼ 27% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 459,832

▼ 24% vs 2024

€ 146,736 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 437,847

▼ 43% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Wages and social charges

€ 141,542

▲ 22% vs 2024

Wages, holiday pay and social contributions still to pay. No outstanding taxes.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 581,990 Gross margin 2022: € 581,990 First fiscal year in the series	€ 872,138 Gross margin 2023: € 872,138 ▲ 50% vs 2022 (€ 581,990) Favourable step	€ 1,038,461 Gross margin 2024: € 1,038,461 ▲ 19% vs 2023 (€ 872,138) Favourable step	€ 1,426,230 Gross margin 2025: € 1,426,230 ▲ 37% vs 2024 (€ 1,038,461) Favourable step	▲ 37%
Profit after taxes	€ -8,226 Profit after taxes 2022: € -8,226 First fiscal year in the series	€ -10,618 Profit after taxes 2023: € -10,618 ▼ € 2,392 vs 2022 (€ -8,226) Unfavourable step	€ -189,421 Profit after taxes 2024: € -189,421 ▼ € 178,803 vs 2023 (€ -10,618) Unfavourable step	€ -76,960 Profit after taxes 2025: € -76,960 ▲ € 112,461 vs 2024 (€ -189,421) Favourable step	▲ € 112,461
Equity	€ 302,624 Equity 2022: € 302,624 First fiscal year in the series	€ 292,007 Equity 2023: € 292,007 ▼ 4% vs 2022 (€ 302,624) Unfavourable step	€ 102,586 Equity 2024: € 102,586 ▼ 65% vs 2023 (€ 292,007) Unfavourable step	€ 25,626 Equity 2025: € 25,626 ▼ 75% vs 2024 (€ 102,586) Unfavourable step	▼ 75%
Total debts	€ 874,607 Total debts 2022: € 874,607 First fiscal year in the series	€ 1,434,201 Total debts 2023: € 1,434,201 ▲ 64% vs 2022 (€ 874,607) Unfavourable step	€ 1,502,960 Total debts 2024: € 1,502,960 ▲ 5% vs 2023 (€ 1,434,201) Unfavourable step	€ 1,039,222 Total debts 2025: € 1,039,222 ▼ 31% vs 2024 (€ 1,502,960) Favourable step	▼ 31%
Cash	€ 441,124 Cash 2022: € 441,124 First fiscal year in the series	€ 607,633 Cash 2023: € 607,633 ▲ 38% vs 2022 (€ 441,124) Favourable step	€ 150,079 Cash 2024: € 150,079 ▼ 75% vs 2023 (€ 607,633) Unfavourable step	€ 56,305 Cash 2025: € 56,305 ▼ 62% vs 2024 (€ 150,079) Unfavourable step	▼ 62%
Retained profit	€ -290,121 Retained profit 2022: € -290,121 First fiscal year in the series	€ -300,739 Retained profit 2023: € -300,739 ▼ € 10,618 vs 2022 (€ -290,121) Unfavourable step	€ -490,160 Retained profit 2024: € -490,160 ▼ € 189,421 vs 2023 (€ -300,739) Unfavourable step	€ -567,119 Retained profit 2025: € -567,119 ▼ € 76,960 vs 2024 (€ -490,160) Unfavourable step	▼ € 76,960
Bank debt	€ 449,872 Bank debt 2022: € 449,872 First fiscal year in the series	€ 729,143 Bank debt 2023: € 729,143 ▲ 62% vs 2022 (€ 449,872) Unfavourable step	€ 607,281 Bank debt 2024: € 607,281 ▼ 17% vs 2023 (€ 729,143) Favourable step	€ 459,832 Bank debt 2025: € 459,832 ▼ 24% vs 2024 (€ 607,281) Favourable step	▼ 24%
Balance sheet total	€ 1,177,232 Balance sheet total 2022: € 1,177,232 First fiscal year in the series	€ 1,726,208 Balance sheet total 2023: € 1,726,208 ▲ 47% vs 2022 (€ 1,177,232) Unchanged	€ 1,605,546 Balance sheet total 2024: € 1,605,546 ▼ 7% vs 2023 (€ 1,726,208) Unchanged	€ 1,064,848 Balance sheet total 2025: € 1,064,848 ▼ 34% vs 2024 (€ 1,605,546) Unchanged	▼ 34%
Employees (FTE)	6.9 Employees (FTE) 2022: 6.9 First fiscal year in the series	10.4 Employees (FTE) 2023: 10.4 ▲ 3.5 vs 2022 (6.9) Unchanged	12.4 Employees (FTE) 2024: 12.4 ▲ 2 vs 2023 (10.4) Unchanged	14.4 Employees (FTE) 2025: 14.4 ▲ 2 vs 2024 (12.4) Unchanged	▲ 2

Key figures of ILiAD Biotechnologies, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to ILiAD Biotechnologies?

What happened at ILiAD Biotechnologies in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 30, 2026 New annual accounts for financial year 2025: loss of € 76,960. filed late Source: NBB ↗
2025 David Hinkel stepped down as director. NBB
2025 David Hinkel became a director. NBB
Jan 15, 2020 New establishment in Gent. KBO
Jan 15, 2020 Start of the company according to the CBE. KBO

In short

From € 8,226 loss in 2022 to € 76,960 loss in 2025.

On average € 99,000 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Thalen Biotech Consultancy BV Rubin Keith

ILiAD Biotechnologies

Behind ILiAD Biotechnologies are Thalen Biotech Consultancy BV and Rubin Keith.

Directors

According to the 2025 annual accounts

Thalen Biotech Consultancy BV

Director · represented by Marcel Thalen

Rubin Keith

Director

David Hinkel

Director

since 2025 · until 2025

Establishments

Establishment units

Physical locations of this company

Registered office

Technologiepark-Zwijnaarde 94

9052 Gent

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.

All companies at this address →

Zomagen Biosciences Belgium

€ 1.2 million gross margin · 2025

AnimAb

€ 28,596 gross margin · 2025

ExeVir Bio

€ -1.2 million gross margin · 2025

Protealis

€ 1.1 million gross margin · 2025

YAKULT HONSHA EUROPEAN RESEARCH CENTER FOR MICROBIOLOGY

+1 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0741.579.648

VAT number

BE 0741.579.648

Registered office

Technologiepark-Zwijnaarde 94, 9052 Gent

Names & denominations

ILiAD Biotechnologies

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

15 January 2020

Peppol

Active · Active since 21 Jan 2026

Contact

[email protected]

Activities · NACE

Speur- en ontwikkelingswerk op biotechnologisch gebied

Vervaardiging van farmaceutische grondstoffen

View on CBE Public ↗ Annual accounts (NBB) ↗

ILiAD Biotechnologies

Warning lights

Financials

What happened to ILiAD Biotechnologies?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions